Vascular Biogenics Ltd. logo

VBLT

Vascular Biogenics Ltd. · NASDAQ

Website

Vascular Biogenics Ltd. (VBLT) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for VBLT in the last 30 days. The most recent was published Feb 16, 2024.

Vascular Biogenics Ltd., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer and immune/inflammatory indications. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-511, an anti-angiogenic candidate for oncology; VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases; and VB-703 for NASH and renal fibrosis. In addition, the company is developing VB-201, a Lecinoxoid-based product candidate to treat atherosclerosis that has completed Phase II clinical; and is in Phase II exploratory trials for COVID-19, as well as in pre-clinical stage for the treatment of NASH and renal fibrosis. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.

Latest news

25 items

VBLT FAQ

8 questions
  • What does Vascular Biogenics Ltd. do?
    Vascular Biogenics Ltd., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer and immune/inflammatory indications. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and...
  • What is the latest news on VBLT?
    Quantisnow has not tracked any new filings, ratings or press releases for VBLT in the last 30 days. The most recent wire item was published on February 16, 2024.
  • Where does VBLT stock trade?
    Vascular Biogenics Ltd. (VBLT) is listed on NASDAQ.
  • What sector and industry is VBLT in?
    Vascular Biogenics Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • When did Vascular Biogenics Ltd. go public?
    Vascular Biogenics Ltd. (VBLT) completed its IPO in 2014.
  • What are analysts saying about VBLT?
    Across the last 4 analyst actions on Vascular Biogenics Ltd., there were 0 upgrades and 2 downgrades. The most recent action was from Oppenheimer: Perform on 2022-07-20. Recent price targets range from $5.00 to $5.50.
  • What companies are similar to VBLT?
    Notable peers in the same industry include JNJ (Johnson & Johnson), MRK (Merck & Company Inc.), NVO (Novo Nordisk A/S), AZN (AstraZeneca PLC), ABT (Abbott Laboratories). Compare VBLT side-by-side with any of them on Quantisnow.
  • How can I track VBLT on Quantisnow?
    Quantisnow aggregates Vascular Biogenics Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VBLT to receive live email and push alerts on every new disclosure.